PhRMA Statement on U.S. Food and Drug Administration’s Emergency Use Authorization for First COVID-19 Vaccine
WASHINGTON, D.C. (December 11, 2020) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl released the following statement:
“Today's historic news that Pfizer and BioNTech’s vaccine candidate for COVID-19 received emergency use authorization from the FDA is nothing short of a stunning scientific achievement. This is the first FDA-authorized COVID-19 vaccine and represents an enormous milestone in our industry's efforts to end this pandemic. This safe, effective vaccine is a direct result of not only the around-the-clock efforts from researchers and scientists, but also the robust biopharmaceutical ecosystem that allowed for such an impressive display of nimble, smart work."
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 trillion in the search for new treatments and cures, including an estimated $83 billion in 2019 alone